Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its antidepressant effect ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...

While Spravato’s underlying mechanisms remain unclear and only ... but one of its two primary components called esketamine. The end result, Spravato has since been approved in 77 countries ...

for SPRAVATO ® (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD) who have had an inadequate ...

6 The mechanism by which esketamine exerts its antidepressant effect is unknown. Backed by more than a decade of research and almost six years of real-world evidence, SPRAVATO ® has proven to be ...